Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UNIPROT:P02794 (ferritin)
 17,525 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Blood serum levels of ferritin and trophoblastic globulin were measured by immunoassay in 389 and 114 cases, respectively, suffering malignant or benign tumors of the uterus and ovary as well as in controls. Hyperferritinemia identified at serum ferritin levels in excess of 200 micrograms/l was established in 94% of cases of ovarian cancer, 57%--benign ovarian tumors, 60%--endometrial carcinoma and in 16% of patients with uterine myoma. Patients with ovarian and uterine malignancies were shown to have the highest serum ferritin levels. The study failed to establish an increase in trophoblastic globulin concentration in cases of nontrophoblastic tumors of the genitals. It is suggested that serum ferritin level be measured in patients presenting with ovarian and uterine tumors and in subjects at high risk for ovarian cancer to assure early diagnosis of disease.
 ...
PMID:[Serum ferritin and trophoblastic globulin in genital tumors in women]. 218 Feb 8

Complex echoscopic, histological and EPR- (electron paramagnetic resonance)-spectroscopic study of uterine smooth muscular tissue was performed using normal and neoplastic samples obtained from women of reproductive age as well as from experimental animals (guinea pigs) with normo- and hyperestrogenemia. It was found that as compared with normal myometrium, the proliferating uterine myoma had an extensive peripheral vascularization of myomatous nodule with a decreased resistance index, which is a marker of myocyte proliferative activity in the myomatous nodule. These data were supported by histological findings in material obtained at operations, which demonstrated the signs of proliferative growth. Using EPR, it was shown that uterine myoma was characterized by an estrogen-dependent intensification of the processes of free-radical oxidation, which correlated with a degree of hormonal changes. Accumulation of free-radical oxidation activators and of ions of ferritin-unbound iron in the tumor tissue is indicative of the intensification of proliferative activity of the cells of uterine myoma and is one of the risk factors of neoplastic growth. Hyperestrogenemia, characteristic for the myoma development, is one of the reasons for NO synthesis activation, which, in the oxidative stress, is transformed into cytotoxic peroxinitrite, contributing to further intensification of an oxidative stress and malignant transformation of tissues.
 ...
PMID:[Oxidative metabolism of uterine smooth muscular tissue in norm and neoplastic growth (clinical and experimental studies)]. 1638 15

A 39-year-old woman was admitted to our hospital with an eight-month history of dyspnea on exertion, weakness and increasing fatigue. She reported repeated episodes of menometrorrhagia and underwent a myomectomy. She is not a vegetarian. Her menstrual bleeding: 3-5 days per month. Two months ago, she complained of burning sensation of the tongue upon swallowing food and noted brittle nails. She tolerated soft foods. On physical examination, she was pale; her nails were very thin, fragile and somewhat concave. Her oral examination showed angular stomatitis, depapillated tongue and glossitis. The clinical diagnosis was anemia and dysphagia. Laboratory tests were: Hb: 7.0g/dL, MCV: 57.42fL, MCH: 15.82 pg; leukocytes: 4,980; reticulocytes: 2.18%, reticulocyte index: 0.1%, serum iron: 21ug/dl, total iron binding capacity (TIBC): 286, transferrin saturation: 7% and serum ferritin: 27ng/ml. The peripheral blood smear showed anisocytosis and hypochromic microcytic cells. Thevenon test was negative. Abdominal ultrasound: uterine myoma. A barium swallow X-ray showed a 2-mm linear filling defect between the 4th and 5th cervical vertebrae in the anteroposterior and lateral view; it protruded from the anterior wall and reduced esophageal lumen by 60%. In the endoscopy, we found a fibrous web in the cricopharyngeal area. Serial dilatations were performed over a guidewire using Savary-Gilliard dilators with diameter up to 14 mm, improving dysphagia. She was treated with transfusional therapy and parenteral iron. She was discharged with ferrous sulfate and folic acid. The Plummer-Vinson syndrome, Paterson-Brown-Kelly or sideropenic dysphagia is characterized by dysphagia, irondeficiency anemia and upper esophageal web. The syndrome is described as very rare.
 ...
PMID:[Plummer-Vinson syndrome: report of a case and review of literature]. 2302 85

A systematic review is done to determine the efficacy and safety of levonorgestrel-releasing intrauterine systems as a treatment using in premenopausal women with symptomatic uterine leiomyoma. We searched the Medline, Central and ICTRP databases for all articles published from inception through July 2013 that examined the following outcomes: uterine volume, uterine leiomyoma volume, endometrial thickness, then menstrual blood loss, blood haemoglobin, ferritin and hematocrit levels, treatment failure rate, device expulsion rate, hysterectomy rate and side effects. From 645 studies, a total of 11 studies met our inclusion criteria with sample sizes ranging from 10 to 104. Evidence suggested that levonorgestrel-releasing intrauterine systems could decrease uterine volume and endometrial thickness, significantly reduce menstrual blood loss, and increase blood haemoglobin, ferritin and hematocrit levels. There was no evidence for decreasing uterine leiomyoma volume. There were no adverse effects on the ovarian function except for ovarian cysts. Device expulsion rates were low, which associated with leiomyoma size (larger than 3cm) but not with leiomyoma location. Irregular bleeding/spotting was observed at the beginning of the follow-up period and then decreased progressively. Results of this systematic review indicate that levonorgestrel-releasing intrauterine systems may be effective and safe treatment for symptomatic uterine leiomyoma in premenopausal women.
...
PMID:Levonorgestrel-releasing intrauterine system use in premenopausal women with symptomatic uterine leiomyoma: a systematic review. 2483 15